AbbVie Inc. · News & developments
AbbVie Showcases Real-World Efficacy to Defend Vraylar's Neuroscience Revenue
At Psych Congress 2026, AbbVie presented prospective real-world observational data evaluating Vraylar (cariprazine) in mood disorders. In the prospective CReW BP-I study in bipolar I depression, patients treated with Vraylar experienced improvements in depressive symptoms, functioning, and quality of life after 12 weeks, with nausea and dizziness as the most common adverse events. Mean MADRS scores dropped from 32.2 at baseline to 19.9 at week 12. In the ProACt study of 76 participants using adjunctive Vraylar for major depressive disorder, mean PHQ-9 scores fell from 15.7 to 7.1 at week 6.
Why this matters
Clinical trials run in sanitized environments, but commercial prescription volume lives in messy community clinics where patients bring complicated comorbidities. For AbbVie, proving that cariprazine retains symptom reduction in unselected outpatient populations gives psychiatric prescribers a practical rationale to keep initiating the branded drug over cheaper generic alternatives and competing atypicals. Because neuroscience revenue is a central pillar supporting operating cash flow as older therapies mature, confirming effectiveness in routine care helps justify formulary placement and protect high-margin prescription volumes.